Conventional serum calprotectin biomarkers are often not as clinically useful as the fecal versions because of the half-life of calprotectin in blood (only 5-6 hours), which leads to dissociation of the calprotectin protein.
Nordic Bioscience developed a novel, blood-based calprotectin biomarker assay that demonstrably quantifies collagen remodeling in Chron's Disease and other diseases.
NASH is often characterized by multiple organ failure, with hepatic cirrhosis driving organ decompensation. But how do we know which organ decompensates first?
We believe it is time to put kidney fibrosis more in the center - even in diseases where other aspects (such as kidney volume) are the focus of attention.
We have examined the effect of copper depletion therapy on the collagen microenvironment in breast cancer patients with high risk of relapse.
If we are to develop precision medicine, we need to identify the right patients. Using Big Data is critical in clinical research, but there is a catch.
Despite its pivotal role, the mechanical load is rarely a component of translational drug screening assays when testing novel osteoarthritis treatments. We want to change that!
Please don't hesitate to contact us if you have any questions or other inquiries.